Opioid peptides comprise a family of active neuropeptides and neurohormones that are processed from large precursor proteins known as pro-opiomelanocortin, preproenkephalin, and preprodynorphin [1] . All opioid peptides share a common N-terminal sequence (TyrGly-Gly-Phe-Leu/Met) which interacts with the mu, delta, and kappa receptors [2] . Several endogenous opioids have been reported: the orphanin FQ peptide which binds to the ORL-1 receptor [3, 4] , and the endomorphins (EMs), consisting of EM1 and EM2 amide tetrapeptides, and displaying a high binding affinity and selectivity to the mu opioid receptor (MOR) [5] [6] [7] . EMs peptides exert a broad spectrum of modulatory bioactivities at both neuroendocrine and cardiovascular systems, including mood, feeding, reproduction, sexual behavior, and pain [8] [9] [10] . Thus, mature EMs are crucial molecules implicated in the regulation of several physiological activities and behaviors in mammalian species; however, its propeptide precursor(s) remain yet to be identified. In 2007, Terskiy et al. performed a bioinformatic study, searching in the current human proteome for putative EM Abbreviations EM1, endomorphin 1; EM2, endomorphin 2; EMs, endomorphins; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ORF, open reading frame; PC1, Proconvertase 1; PC2, Proconvertase 2. precursor proteins. Such proteome screening yielded no evidence for EM precursor protein based on accepted biochemical criteria [11] . Thus, there is no convincing evidence that an endogenous precursor protein for EMs is encoded in the mammalian genome. Given the lack of information about the EM peptide precursor and the availability of specific affinitypurified rabbit antisera raised against either EM1 or EM2 peptides [12] , we decided to pursue an immunological strategy.
Material and methods

Drugs and peptides
Synthetic peptides of EM1 (5 mg), EM2 (5 mg), naloxone, and DAMGO were purchased from Tocris (Baldwin, MO, USA). Mexneurin-1 (Mx-1) was custom synthesized from Biosynthesis Inc. (Lewisville, TX, USA).
Animals
All studies were conducted in accordance with animal care ethics approval and guidelines, as outlined by the National Institutes of Health (NIH, Guide for Care and Use of Animals) and approved in advance by NOM-062-ZOO-1999 (Mexico City) and the Oregon Health & Sciences University Institutional Animal Care and Use Committee. Animals were housed in plastic cages at 22 AE 2°C with a 12:12 h light-dark cycle (08:00 on; 20:00 off) in a temperature-controlled room with food and water ad libitum. Male BALB/c mice were used for RT-PCR assays (25-35 g ) and male Wistar rats (180-220 g) for [
35 S]GTPcS-binding assays and Sprague-Dawley rats for electrophysiological studies.
Immunoscreening
Polyclonal antibodies from rabbits, previously reported [12] , were used against the synthetic EMs. Both antisera, C-14 raised against EM1 (Tyr-Pro-Trp-Phe-NH 2 ) and C-16 raised against EM2 (Tyr-Pro-Phe-Phe-NH 2 ) were used for immunoscreening a whole mouse brain cDNA library (Lambda -ZAP; Stratagene, La Jolla, CA, USA) expressed in XL1-Blue MRF' Escherichia coli strain. A total of 1 9 10 9 plaques were screened according to the manufacturer instructions. The dilution of each serum was 1 : 20. Bound antibodies were detected with a 125 I-conjugated Goat anti-Rabbit IgG, Fc fragment-specific secondary antibody. Positive plaques were excised from the plate and submitted to two further rounds of immunoscreening until purity was achieved. Positive clones were excised to pBlueScript-SK+ plasmid forms according to the manufacturer instructions (Stratagene). Positive clones identified were PCR amplified using T3 and T7 vector-specific primers (Gibco/BRL, Gaithersburg, MD, USA) and was sequenced using the BigDye Terminator Cycle Sequencing kit on an AbiPrism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
Nucleotide and amino acid sequence analysis 
Probes
Two different cRNA probes were generated to hybridize Mexneurins (Mxs) mRNA. PCR templates were generated using Mxs-specific primers with 5 0 extensions of either 13 or 17 RNA polymerase promoters, a method previously described by Logel et al. [14] . PCR amplifications were performed according standard protocols and verified by electrophoresis. ln vitro transcription from the PCR-generated templates was performed using the PROMEGA T7 and T3 in vitro Transcription Kit (Promega, Madison, WI, USA). The correct size of the cRNA probes was verified by electrophoresis. The labeled cRNA probes were purified by phenol/chloroform extraction and ethanol precipitation and stored in ethanol al À70°C until used. The cRNA probe generated from Mxs cDNA template was sized into fragments averaging 300-500 nucleotides long by limited alkaline hydrolysis. In situ hybridization was performed as described by Zheng and Pintar [15] . Areas expressing Mxs mRNAs were determined as positive after detecting grain densities at least three times higher than the background density in cell bodies. Background levels were determined from adjacent control sections hybridized with a sense cRNA probe or antisense cRNA probe in sections pretreated with RNase A.
Microscopy analysis
Brain sections were observed under bright-field illumination using a DAS LEIKA DMR Qwin-microscope. The neuroanatomical areas displaying positive hybridization signals in cells and brain regions were identified according to the atlas of the rat brain of Paxinos and Watson [16] . In all experiments, basal binding was assessed in the absence of drug, and nonspecific binding was measured in the presence of 10 lM unlabeled GTPcS. All incubations were terminated by rapid filtration under vacuum through Whatman GF/B glass fiber filters, followed by three washes with 3 mL of ice-cold 50 mM Tris-HCI, pH 7.4. Bound radioactivity was determined by liquid scintillation spectrophotometry at 95% efficiency for 35 S, after overnight extraction of the filters in 5 mL Scinti Verse scintillation fluid.
Data analysis and statistics
Graphs were fitted using the SIGMAPLOT 10.0 Software (Systat Software, Inc., San Jose, CA, USA). Data are expressed as mean AE SEM.
Electrophysiological studies
Preparation of brain slices
Sprague-Dawley rats (20-24 days old) were deeply anesthetized with halothane, their brains removed and submerged in ice-cold artificial cerebrospinal fluid (ACSF) containing (in mM): NaCl 87, KCl 2.5, NaH 2 PO 4 1.25, NaHCO 3 25, MgCl 2 7, CaCl 2 0.5, glucose 25, and sucrose 75 saturated with 95% O 2 /5% CO 2 . Coronal (250 lm) slices containing the hypothalamus were prepared on a vibratome (Leica VT 1000S, Nussloch, Germany). Slices were transferred first to a holding chamber in which the temperature was gradually raised to 35°C over 30 min. Then, individual slices were transferred to the recording chamber in which they were completely submerged in 32°C ACSF (same as above, except MgCl 2 1.2, CaCl 2 2.4 mM). Experiments were performed with cells visualized using infrared differential interference contrast microscopy (IR-DIC, Leica DMLFS microscope).
Patch clamp recording
Electrodes used for patch clamp recordings had outside tip diameters of~1 lm and resistances of~5-8 MΩ when filled with internal solution containing (in mM): K-gluconate 110, KCl 40, MgCl 2 2, HEPES 10, EGTA 0.1, ATP 2, pH 7.2. The electrode was advanced into the brain slice and a seal with the cell membrane (resistance: 2-15 GΩ) was obtained by applying negative pressure. After further negative pressure to rupture the membrane and obtain whole-cell recording mode, current clamp and/or voltage clamp experiments were performed. Peptides Mx-1 (1 lM), Mx-2 (1 lM), or Mx-3 (10 nM-1 lM) were bath applied, as was the mu opioid receptor antagonist CTOP (100 nM; Tocris), and the currents or voltages were measured with an Axopatch-1D amplifier (Axon Instruments, Foster City, CA, USA) and saved on an on-line computer (Macintosh) equipped with PULSE and PULSEFIT software (HEKA, Lambrecht Germany). Data were analyzed in Microsoft Excel and GraphPad Prism (La Jolla, CA, USA).
Results
Immunoscreening and characterization of proMexneurin mRNA
Our immunoscreening assay led to the identification of a full-length 1.083-kb cDNA clone (NCBI accession AY142705.1.). This cDNA encodes a predicted putative mature protein of 91 amino acids, which was named proMexneurin. An alignment analysis using the NCBI Blast+ with the nucleotide sequence showed a 100% identity with the nucleotide sequence of the MCG119713, isoform CRA_a of Mus musculus, and a similarity of 14-56% with different uncharacterized nucleotide sequences in diverse organisms such as Cricetulus griseus and Nematostella ventensis. As shown in Fig. 1 , proMexneurin cDNA consists of an ORF of 91 bp, with an initiation codon (ATG) at positions 270-272 and a stop codon (TAG) at positions 543-545. The ORF is flanked by 270 bp at the 5 0 UTR and 538 bp at the 3 0 UTR, respectively, which contains a polyadenylation signal-5 0 -AATAAA-3 0 -at positions 1046-1051 of the nucleotide sequence, ending with a poly-A tail. The protein sequence of proMexneurin protein has the NCBI accession number AAN28928. A PSI-BLAST analysis of the amino acid sequence shows a 100% identity with the MCG119713 protein sequence of M. musculus (UniProtKB ID: I6L9U2_MOUSE; accession CH466552), and a 56% of identity with an uncharacterized hypothetical protein of Cricetulus griseus (UniProtKB ID: G3HYP4_CRIGR and accession JH000938.1). From the deduced amino acid sequence, the1-39 N-terminal residues of the consensus sequence defines a cleavage site of a signal peptide in a structural secretory protein, following the (À3, À1) von Heijne rule [18] . The predicted polypeptide appears to contain three potential mature peptides. Based on the rules of neuropeptide processing [19] ; the first peptide was predicted to be a eight-amino acid peptide sequence, from residues 40-47 (Thr-8-Phe) and named Mexneurin-1 (Mx-1), the second peptide consists of nine amino acids, corresponding to residues 50-58 (Thr-9-Ser) and named Mexneurin-2 (Mx-2); the third predicted peptide consist of a C-terminal, 31-amino acid peptide sequence from residues 61-91 (Pro-31-Cys), and named Mexneurin-3 (Mx-3).
RT-PCR amplification of the proMexneurin mRNA PCR amplification of the proMexneurin cDNA successfully amplified a single product of 391 bp from the total RNA extracted from both neural and extraneural tissues. As is shown in Fig. 2A , the proMexneurin gene transcript was widely expressed in mouse neuronal tissue such as the retina, olfactory bulb, cortex, hippocampus, thalamus, mesencephalon, brainstem, cerebellum, spinal cord, and from extraneuronal tissues, such as the spleen. proMexneurin mRNA expression was not detected in non-neuronal tissues tested, such as the gut, liver, kidney, and lung (data not shown). 52 mm, and (h) À5.6 mm relative to bregma [16] . (C) The promexneurin mRNA relative expression in 10 areas with the highest expression of whole coronal and sagittal sections and some hypothalamic nuclei, labeled at (B), are represented. The relative density of in situ signals in the brain areas was determined using IMAGEJ Software (NIH, Bethesda, MD, USA). After subtraction of the background, the mean optical density of a brain region was used for comparisons. Abbreviations are defined in the legend above (B).
A
Neuroanatomical distribution of proMexneurin mRNA
In situ hybridization revealed a widespread distribution of proMexneurin mRNA throughout the mouse brain (Fig. 2B,C and Table S1 ). By far, the most densely labeled areas were observed in trigeminal nerve (5n), followed by limbic structures, such as the CA3 and CA2 areas of the hippocampus and BMP; thalamic nuclei (VMP, MHb, Po, DLG), olfactory bulb (Mi), and caudate-putamen (CPu), respectively. Moderate to low mRNA densities were detected in hypothalamic nuclei (DMD, DMV, SuMM, and MM) (Fig. 2C) . However, high to moderate mRNA expression was observed in cerebral cortex, distributed throughout layers I and IV in fronto-orbital cortices (113-180). Hybridization signals detected in both cingulate (126) and retrosplenial cortices (140) were similar to that observed in both neocortex (108) and primary olfactory cortex (106), showing a high expression in cell bodies distributed within layers II-III and IV-V, respectively). The olfactory tract (Lo) displayed the highest relative density of proMexneurin mRNA (142); whereas moderate hybridization levels of the mRNA was observed in the nucleus accumbens (106) ( Table S1 ).
Functional characterization of Mexneurins
Mexneurins-dependent stimulation of [
S]GTPcS
To assess relative agonist efficacy of peptides Mx-1, -2, and -3, we measured GPCR activation by direct activation of Ga subunits using [ 35 S]GTPcS binding. This assay assesses receptor activation by measuring guanine nucleotide exchange, an early event in GPCRmediated signaling [20] . Mx-1 and Mx-3 as ligands stimulated the incorporation of [ 35 S]GTPcS into the rat hippocampus membranes, displaying a range of potency and intrinsic activity (Fig. 3) . Mx-1 stimulated 
Electrophysiological studies
For Mx-1, 99 cells in the rostral supraoptic nucleus (SON) and 12 cells in the suprachiasmatic nucleus (SCN) of the hypothalamus were recorded for responses to Mx-1. Due to Mx-1 sequence similarity to conserved regions of the endogenous l-opioid agonists EM1 and EM2 [5] , we examined the hypothesis that Mx-1 might display electrophysiological activity in a hypothalamic region known to respond to l-opioid agonists. Consistent with this hypothesis, 12 cells recorded from the SCN, which has been shown to be largely unresponsive to l-agonists [21] , did not respond to Mx-1 by a reduction of spontaneous firing rate (SFR). In contrast, 32 of 99 cells in the rostral subdivision of the SON responded to Mx-1. SFR was strongly inhibited in response to focal application of Mx-1 (Fig. 4A) , similar to previous findings using EM1 [22] . To establish a dose-response relationship of Mx-1, a total of 85 neurons were recorded in whole-cell mode, of which 28 responded with an outward current (Fig. 4B-D) to bath application of MX-1 at concentrations between 10 nM and 100 lM when held at a relatively depolarized membrane potential (À50 mV) compared to the average membrane resting potentials reported previously (À62 mV [23] ). Since it was difficult to determine whether neurons were responsive to Mx-1 concentrations below 10 nM (3 and 1 nM), these results were excluded from the dose-response experiments. The evoked current was dose-dependent (10 nM: 19.6 AE 3.1 pA, n = 5; 30 nM: 33.0 AE 2.1 pA, n = 3; 100 nM, 49.6 AE 6.0 pA, n = 5; 300 nM: 68.0 AE 4.2 pA, n = 3; 1 lM: 94.0 AE 13.1 pA, n = 3; 100 lM: 89.0 AE 12.6 pA, n = 3; EC 50 = 76.6 nM, Fig. 4E) , and reversed at À105 mV (Fig. 4F) , consistent with a K-current (calculated reversal: À103 mV). K-conductances in response to l receptor activation have been shown in the SON [22, 24] . To examine whether Mx-1 acts through the l receptor in the SON, we tested whether the l receptor antagonist CTOP could inhibit the response to 100 nM Mx-1. Six SON neurons were allowed to maximally respond to bath application of Mx-1 (42.2 AE 7.2 pA). Adding CTOP (100 nM) to the bath reduced the current amplitude gradually to 3.8 AE 2.0 pA. After antagonist washout, the MX-1-mediated currents returned to 31.0 AE 8.3 pA. Additionally, six cells in the SCN and six in the SON were tested for responses to 1 lM Mx-2 and Mx-3 each and no measurable difference in either SFR or holding current was detectable. Together, these results suggest Mx-1 may act as a l-receptor agonist.
Discussion
Our results from the immunoscreening assay show the cloning and molecular characterization of a putative mammalian protein precursor, which we named proMexneurin. The predicted polypeptide contains three potentially mature peptides, based on the rules of neuropeptide processing [19] . A single copy of an opioid-like peptide motif of eight amino acids (NH 2 -TFSGYPAF-COO À ), Mx-1, was identified in the proMexneurin protein sequence. This peptide was shown to be flanked by basic (R) and dibasic (RK) amino acids at the N-terminal and C-terminal domain, respectively, of the predicted sequence, suggesting they serve as a signal site for peptide cleavage via PC1 and PC2 enzymes (see [25, 26] , for reviews). We propose that proMexneurin is a member of type IV precursors; this group includes proteins cleaved at either single o-paired residues. The difference between these proteins and the type I-III precursors is the characteristic presence of two C-terminal residues (either R or K) to cleavage site [19] .
Adjacent to the dibasic cleavage signal site in the Mx-1 peptide; a second peptide of nine amino acids (NH 2 -TSRTDGTQS-COO À ) was identified, Mx-2. This peptide is flanked by a pair of basic residues (-RK-and RR-). Adjacent to Mx-2, there is an additional C-terminal peptide of 31 amino acid residues (NH 2 -PPPRSPYSGKGLGPGNLLHSALLPIHCICLC-COO À ), Mx-3. This peptide showed a -CXC-like peptide motif at its C-terminus domain, similar to that found at CXC chemokines (i.e., GROa/CXCL1, PF4/ CXCL4, IL-8/CXCL8, IP-10/CXCL10, SDF-1/ CXCL12; see [27] for review), suggesting that Mx-3 may represent a chemokine-like peptide.
Distribution of Mexneurin mRNA in the brain
To identify the tissue distribution of Mexneurin peptides in the mouse CNS and characterize a plausible Mexneurin system in the mammalian brain, we mapped the Mexneurin mRNA expression along the neuraxis of the mouse CNS. RT-PCR and in situ hybridization studies revealed a widespread distribution of this mRNA throughout the mouse brain. Intense expression of Mexneurin mRNA was detected in the olfactory cortex and olfactory bulb, suggesting a plausible role of Mexneurin peptides in olfactory function. Subcortical regions, such as the basal ganglia, thalamic-hypothalamic nuclei, amygdala and hippocampus showed high labeling of Mexneurin mRNA, suggesting a role of the peptides in these limbic regions. It is worth noting that the cortical regions with high proMexneurin mRNA expression-frontoorbital, cingulate, and retrosplenial-also have reciprocal innervation with thalamic areas. Furthermore, brainstem structures such as the pons and medulla exhibited high densities of proMexneurin mRNA, suggesting wide and varied regulatory roles of Mx peptides in hindbrain nuclei and cells (i.e., autonomic, cardiac and respiratory functions, alert and waking activities, sleep cycle, eating behavior, regulation of motor and sensory systems, among many others) [28, 29] . Similarly, moderate levels of Mexneurin mRNA were detected in Purkinje cells, suggesting that Mx mRNA-derived peptides may play important physiological roles in reflex movement, balance, and body equilibrium [30, 31] . Comparing the brain distribution of different opioid propeptide mRNAs to Mexneurin mRNA, the latter exhibited a grossly similar mRNA distribution with respect to that shown for prepronociceptin and proenkephalin; but fairly distinct from the prodynorphin mRNA [31] . Mexneurin mRNA was also found in hypothalamic nuclei (DMD, DMV, and mammillary nucleus). Nonetheless, further studies are needed to delineate the plausible physiological roles of Mx peptides in each of these brain regions.
Opioid peptide immunoreactivity (IR) in projection fibers overlaps largely with the localization of opioid receptors (for detailed information see Le Merrer et al.
[31]). In general, major sites of Mexneurin mRNA observed in the brain matched the mRNA distribution detected for MOR [32] . However, further information is needed to assess the inmunohistochemical correlation between Mexneurinx mRNA expression and localization of Mx peptides and their cognate receptors in brain regions and neurons, respectively. In addition, the identification of the subcellular sites of expression and storage of Mexneurin peptides remains crucial to elucidate their mechanisms of action, for instance, as synaptic or nonsynaptic modulators, including the plausible interaction of these peptides with other molecules involved in neurotransmission. Additionally, a single propeptide often produces multiple peptides, and propeptides may not be processed the same way in different cell types or even within the same cell type under different conditions. This is noteworthy because post-translational cleavage and post-translational modifications can affect binding affinities, as well as regulate the bioactivity and stability of the peptides [33] . 
S]GTPcS-binding assays
The hippocampus showed high expression of proMexneurin mRNA, and due to the structural organization of cells in compact cell layers and the stratification of afferent fibers and synapses impinging on the dendritic tree of principal cells, we used this brain area to explore [ 
Electrophysiological studies
Our electrophysiological studies show that Mx-1 K-conductances evoke electrophysiological responses as a result of l receptor activation in hypothalamic regions (i.e., SON) as previously demonstrated for EM1 and other l-opioid agonists [22, 24] . Furthermore, the currents evoked in the SON display sensitivity to the l-opioid antagonist CTOP. Taken together, these results are consistent with a putative role for this peptide as an endogenous l-opioid receptor agonist.
Accordingly to our results of the functional characterization of Mx-1 we propose that this peptide represents a hitherto unidentified opioid peptide. The opioid-like peptide motif of Mx-1 exhibits structural similarity with the consensus amino acid sequence of EMs, Tyr-Pro-Trp/Phe-Phe, with an alanine residue placed in position 3. Based on the message-address concept, opioid sequences have been subdivided into two functional parts. Thus, the message part of the N-terminal part of the peptide sequence is crucially necessary for receptor recognition, whereas the address part of the peptide motif provides the receptor selectivity [32], although, these subunits vary extremely among different opioids. Mx-1 satisfies the requirement of the general consensus of the phenolic OH group of an N-terminal Tyr residue with a free cationic a-amino group (similar to the tyramine moiety of morphine). Similarly, Mx-1 keeps an aromatic amino acid separated by one or two residues. These structural characteristics were shown to meet key requirements of opioid peptides binding to GPCRs. Furthermore, the nonacidic but the polar function of the C-terminal residue was found essential for MOR binding of EMs, a chemical criterion that Mx-1 peptide clearly fulfills.
Our findings suggest that further experimental work needs to be performed on Mx-1 peptide, in order to confirm its role as an opioid agonist, in addition to exploring how this peptide may mediate its biological functions on both mu, delta, and kappa opioid receptors. Furthermore, it should be interesting to explore the mechanisms of action of the Mx-1, searching for the cellsignaling pathways that this peptide may recruit when exerting its opioid and nonopioid effects in the CNS. 30 
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